Drug major Lupin and Swiss Garnier Life Science moved the Delhi High Court on Monday, challenging the government’s decision to fix the price of their anti-asthma drug Doxyflline. In their petition, Lupin and Garnier Life Science challenged the National Pharmaceutical Pricing Authority circular, in which it has put its two medicines under the first schedule of the Drug Price Control Order of 1995.
Top Section
Explore Business Standard